Literature DB >> 10926740

Lupus erythematosus tumidus--a neglected subset of cutaneous Lupus erythematosus: report of 40 cases.

A Kuhn1, D Richter-Hintz, C Oslislo, T Ruzicka, M Megahed, P Lehmann.   

Abstract

BACKGROUND: Lupus erythematosus tumidus (LET) is characterized clinically by erythematous, succulent, edematous, nonscarring plaques in sun-exposed areas. Results of histological examination show perivascular and periadnexal lymphocytic infiltration and interstitial mucin deposition. The main differential diagnoses are polymorphous light eruption, Jessner's lymphocytic infiltration of the skin, reticular erythematous mucinosis, and pseudolymphoma. Since its first description in 1930, LET has been documented rarely in the literature, and its clinical importance has not been fully appreciated. OBSERVATIONS: We characterized 40 patients with clinical and histological features of LET observed at our department from 1984 through 1998. The onset of the disease clustered in summer because of sun exposure, and 28 (70%) of the patients showed a remarkable photosensitivity confirmed by results of provocative phototesting. A complete resolution of the skin lesions was seen after systemic therapy with antimalarials and, in some cases, with local corticosteroids or spontaneously without any treatment. In 4 (10%) of the patients, antinuclear antibodies were detected; however, there was no evidence of underlying systemic involvement in any of the patients.
CONCLUSIONS: Our data constitute the largest number of patients with LET collected until now. The clinical picture, extreme photosensitivity, histological findings, and effective treatment with antimalarials are so characteristic that LET should be considered as a separate entity and differentiated from other variants of cutaneous LE. Arch Dermatol. 2000;136:1033-1041

Entities:  

Mesh:

Year:  2000        PMID: 10926740     DOI: 10.1001/archderm.136.8.1033

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  26 in total

1.  [Topical treatment with tacrolimus in lupus erythematosus tumidus].

Authors:  D Bacman; A Tanbajewa; M Megahed; T Ruzicka; A Kuhn
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

2.  [Cutaneous lupus erythematosus. Part 1: clinical manifestations and classification].

Authors:  A Kuhn; K Gensch; S Ständer; G Bonsmann
Journal:  Hautarzt       Date:  2006-03       Impact factor: 0.751

3.  [Extreme photosensitivity since childhood].

Authors:  A Kuhn; S Hanneken; M Megahed; T Ruzicka; N J Neumann
Journal:  Hautarzt       Date:  2006-01       Impact factor: 0.751

4.  [Skin manifestations in lupus erythematosus: clinical aspects and therapy].

Authors:  A Kuhn; V Ruland; G Bonsmann
Journal:  Z Rheumatol       Date:  2011-04       Impact factor: 1.372

5.  Coexistence of tumid lupus erythematosus with systemic lupus erythematosus and discoid lupus erythematosus: a report of two cases of tumid lupus.

Authors:  Jennifer Stead; Catherine Headley; Michael Ioffreda; Carrie Kovarik; Victoria Werth
Journal:  J Clin Rheumatol       Date:  2008-12       Impact factor: 3.517

6.  [Reticular erythematous plaques].

Authors:  A T Onken; B Belloni; C Schnopp; R Hein; M Mempel; J Ring
Journal:  Hautarzt       Date:  2009-02       Impact factor: 0.751

7.  Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.

Authors:  Rachel S Klein; Pamela A Morganroth; Victoria P Werth
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

Review 8.  The Cutaneous Spectrum of Lupus Erythematosus.

Authors:  Simone Ribero; Savino Sciascia; Luca Borradori; Dan Lipsker
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 9.  Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation.

Authors:  Thrasivoulos George Tzellos; Dimitrios Kouvelas
Journal:  Eur J Clin Pharmacol       Date:  2007-12-20       Impact factor: 2.953

Review 10.  Cutaneous lupus erythematosus: diagnosis and treatment.

Authors:  L G Okon; V P Werth
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-06       Impact factor: 4.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.